We engage with multinational payers and physicians to gather and analyze results from qualitative interviews. These results can identify reimbursement considerations for making a value case for your technology and enable you to identify gaps in evidence plans and value propositions for payers. This information is often combined with feedback from clinical key decision- makers to inform your market access strategy.
Payers (e.g., CMS and US commercial payers, CADTH, NICE) are more open to “early engagement” with manufacturers to discuss clinical and economic evidence development plans that characterize the value of their new health technology.
We conduct qualitative and quantitative payer/physician research to help our clients understand the critical issues. Specifically, we develop early payer and physician engagement strategies and approaches, which include:
Payer and Physician interviews
Payer and Physician surveys
Advisory boards
Mock Pharmacy and Therapeutics (P&T) Committees
We help clients understand the clinical and economic needs of payers. Early engagement with payers and health care providers ideally starts during Phase 2a. This market access strategy can inform your clinical team of key clinical and economic endpoints for Phase 3 study design.
Related Services
For your projects that may have cross-functional requirements, we also offer the following complementary services:
